Faculty of Medicine, Department of Biostatistics and Medical Informatics, Karadeniz Technical University, Trabzon, Turkey.
Dentistry Faculty of Dentistry, Department of Pediatric, Karadeniz Technical University, Trabzon, Turkey.
J Biomol Struct Dyn. 2022 Oct;40(17):7656-7665. doi: 10.1080/07391102.2021.1900919. Epub 2021 Mar 22.
The recent outbreak of COVID-19 caused by a new human coronavirus called SARS-CoV-2, is continually causing worldwide human infections and deaths.The main protease (3CLpro), which plays a critical role in the life cycle of the virus, makes it an attractive target for the development of antiviral agents effective against coronaviruses (CoVs).Currently, there is no specific viral protein targeted therapeutics.Therefore, there is a need to investigate an alternative therapy which will prevent the spread of the infection, by focusing on the transmission of the virus.Chlorhexidine (CHX) and flavonoids agents have shown that they have a viral inactivation effect against enveloped viruses, and thus facilitate the struggle against oral transmission.Especially, some flavonoids have very strong antiviral activity in SARS-CoV and MERS-CoV main protease.This study was conducted to evaluate the CHX and flavonoids compounds potential antiviral effects on SARS-CoV-2 main protease through virtual screening for the COVID-19 treatment by molecular docking method.According to the results of this study, CHX, Kaempferol-3-rutinoside, Rutin, Quercetin 3-beta-D-glucoside and Isobavachalcone exhibited the best binding affinity against this enzyme, and also these compounds showed significant inhibitory effects compared to the SARS-CoV-2 main protease crystal structure inhibitor (N3).Especially, these compounds mainly interact with and in SARS-CoV-2 main protease binding site. Further, MD simulation analysis also confirmed that stability of these interactions between the enzyme and these five compounds.The current study provides to guide clinical trials for broad-spectrum CHX and bioactive flavonoids to reduce the viral load of the infection and possibly disease progression.Communicated by Ramaswamy H. Sarma.
最近由一种新型人类冠状病毒 SARS-CoV-2 引起的 COVID-19 持续在全球范围内引发人类感染和死亡。在病毒的生命周期中起着关键作用的主要蛋白酶(3CLpro),使其成为开发针对冠状病毒(CoVs)的有效抗病毒药物的有吸引力的靶标。目前,尚无针对特定病毒蛋白的靶向治疗药物。因此,需要研究一种替代疗法,通过关注病毒的传播来阻止感染的传播。洗必泰(CHX)和类黄酮类药物已表明它们对包膜病毒具有病毒灭活作用,从而有助于对抗口腔传播。特别是,一些类黄酮在 SARS-CoV 和 MERS-CoV 主要蛋白酶中具有很强的抗病毒活性。本研究通过分子对接方法进行虚拟筛选,评估 CHX 和类黄酮化合物对 SARS-CoV-2 主要蛋白酶的潜在抗病毒作用,以期为 COVID-19 的治疗提供依据。根据本研究的结果,洗必泰、山奈酚-3-芸香糖苷、芦丁、槲皮素 3-β-D-葡萄糖苷和异甘草素对该酶表现出最佳的结合亲和力,并且与 SARS-CoV-2 主要蛋白酶晶体结构抑制剂(N3)相比,这些化合物也表现出显著的抑制作用。特别是,这些化合物主要与 SARS-CoV-2 主要蛋白酶结合位点中的 和 相互作用。进一步的 MD 模拟分析也证实了这些酶与这五种化合物之间相互作用的稳定性。本研究为临床广泛应用洗必泰和生物活性类黄酮以降低感染病毒载量并可能减缓疾病进展提供了指导。通讯作者为 Ramaswamy H. Sarma。